US Edition
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
- Pfizer will share details on the initial human trial protocol for MesoC2, a mesothelin-targeting antibody-drug conjugate , during the 2025 ASCO Annual Meeting in Cambridge, Massachusetts.
- This presentation follows Pfizer’s licensing of MesoC2 from Nona Biosciences in December 2023 and initiates a Phase 1 open-label trial evaluating safety and preliminary efficacy.
- The Phase 1 study plans to enroll up to 365 individuals with various advanced solid malignancies, such as mesothelioma, platinum-resistant ovarian cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer, endometrial cancer, and colorectal cancer.
- MesoC2 is a novel antibody-drug conjugate combining a human IgG1 anti-MSLN antibody with a cleavable linker attached to a topoisomerase 1 inhibitor, featuring an average of eight drug molecules per antibody, and demonstrating strong antitumor activity and a favorable safety profile in preclinical studies.
- The trial's initiation marks a key milestone in the collaboration, underscoring a shared commitment to addressing unmet oncology needs while further trial details will be presented at ASCO on June 2, 2025.
27 Articles
27 Articles
The Courier-Tribune
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study…
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting - PressReach
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (A…
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
